USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy

Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wenjun, Gao, Xueliang, Zhang, Tiantian, Jiang, Baishan, Hu, Ming-Ming, Bu, Xia, Gao, Yang, Zhang, Lin-Zhou, Xiao, Bo-Lin, He, Chuan, Sun, Yishuang, Li, Haiou, Shi, Jie, Xiao, Xiangling, Xiang, Bolin, Xie, Conghua, Chen, Gang, Zhang, Haojian, Wei, Wenyi, Freeman, Gordon J., Shu, Hong-Bing, Wang, Haizhen, Zhang, Jinfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971425/
https://www.ncbi.nlm.nih.gov/pubmed/35361799
http://dx.doi.org/10.1038/s41467-022-29401-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971425/
https://www.ncbi.nlm.nih.gov/pubmed/35361799
http://dx.doi.org/10.1038/s41467-022-29401-6

Ejemplares similares